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It has been suggested that the programming of the endocrine
axes occurs during critical phases of fetal development and
will be affected by intrauterine growth retardation. As a re-
sult, children born small for gestational age (SGA) might have
several hormonal disturbances. In later life, one of the ques-
tions that might arise is: Do short children born SGA have
higher serum dehydroepiandrosterone sulfate (DHEAS) lev-
els than their peers? Therefore, we compared serum DHEAS
levels of 181 short prepubertal children aged 3–9 yr born SGA
[birth length (SD score) below 2 for gestational age] with a
control group of 170 prepubertal age-matched, normal-stat-
ured children born appropriate for gestational age (birth
length between 2 and 2 SD score). Because relatively high
serum DHEAS levels at a young age might result in a prema-
ture pubarche, we investigated the incidence of premature
pubarche. We also investigated the association between se-
rum DHEAS levels and bone maturation. In addition, we an-
alyzed whether 1 yr of GH treatment with 1 and 2 mg/m2d
(0.035 and 0.070 mg/kgd, respectively) had an effect on se-
rum DHEAS levels of prepubertal short SGA children.
Serum DHEAS levels of the SGA group were comparable
with those of age-matched appropriate for gestational age
controls. The incidence of premature pubarche was compa-
rable with that of the normal population. There was a weak
negative correlation between serum DHEAS levels and bone
maturation after the age of 7 yr. After 1 yr of GH treatment, the
increase of serum DHEAS levels was the same for both GH
dosage groups and the untreated group.
In conclusion, this study shows that small size at birth,
which might be a feature of fetal growth restriction, has no
effect on serum DHEAS levels before the age of 9 yr. The
incidence of premature pubarche is comparable with the nor-
mal population. Finally, 1 yr of GH treatment has no effect on
serum DHEAS levels. (J Clin Endocrinol Metab 89: 712–717,
2004)
EPIDEMIOLOGICAL STUDIES HAVE shown a correla-tion between low birth weight and hypertension, di-
abetes mellitus type II, hyperlipidemia, and cardiovascular
disease at a relatively young age (1). It has been suggested
that the programming of the endocrine axes occurs during
critical phases of fetal development, which will be affected by
intrauterine growth retardation (2–4). As a result, children
born small for gestational age (SGA) might have several
hormonal disturbances during later life.
One of the unresolved questions is whether children born
SGA without catch-up growth have a disturbed adrenarche,
the prepubertal rise in the secretion of the adrenal steroids
dehydroepiandrosterone (DHEA), dehydroepiandrosterone
sulfate (DHEAS), and androstenedione, and whether these
children are at increased risk for a premature pubarche.
Premature pubarche is defined as the appearance of pubic
hair growth before the age of 8 yr in girls and 9 yr in boys
and is mostly accompanied by axillary hair, acne, and pu-
bertal odor (5, 6). Some studies have reported higher DHEAS
levels in children born SGA (7, 8), but other studies did not
confirm these results (9). A possible explanation for these
discrepancies could be that various definitions for low birth
weight, SGA, and catch-up growth were used. Premature
pubarche might be caused by relatively high serum DHEAS
levels at a young age. Studies in adolescent girls indicated
associations between low birth weight and the occurrence of
premature adrenarche, pubarche, hyperandrogenism, poly-
cystic ovarian syndrome, and hyperinsulinism (10). These
findings might have serious consequences for later life.
DHEAS arises primarily from the adrenal cortex, has a
relatively long half-life in the circulation, and, therefore, does
not exhibit a circadian rhythm (6, 11–13). For that reason,
determination of serum DHEAS levels is appropriate for
evaluation of adrenarche.
In the first part of our study, we assessed whether short
prepubertal children aged 3–9 yr born SGA had serum
DHEAS levels that differ from those in normal-statured,
age-matched children born appropriate for gestational age
(AGA). In addition, we investigated the incidence of pre-
mature pubarche in short children born SGA and whether
there was an association between serum DHEAS levels and
bone maturation in SGA children.
Many children born SGA without a catch-up growth are
being treated with GH. Therefore, in the second part of this
Abbreviations: AGA, Appropriate for gestational age; BA, bone age;
BMI, body mass index; CA, chronological age; DHEA, dehydroepi-
androsterone; DHEAS, DHEA sulfate; SDS, sd score; SGA, small for
gestational age.
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study we evaluated the effect of GH treatment (1 or 2 mg/
m2d) on serum DHEAS levels in short children born SGA.
Patients and Methods
Study groups
The SGA group was comprised of 181 prepubertal children (91 boys
and 90 girls) with short stature born SGA. They were enrolled between
1991 and 2001 in two Dutch multicenter GH trials in which short children
born SGA were treated with GH. The following inclusion criteria were
used: 1) birth length below 2 sd for gestational age according to the
standards of Usher and McLean (14); 2) an uncomplicated neonatal
period; 3) height sd score (SDS) for chronological age (CA) below2.00
according to Dutch references (15); 4) height velocity SDS for CA less
than or equal to zero to exclude children presenting spontaneous
catch-up growth (15, 16); 5) normal liver, kidney, and thyroid functions;
6) prepubertal stage defined as Tanner breast stage I for girls, and
testicular volume less than 4 ml for boys (17); and 7) age between 3 and
9 yr. Exclusion criteria were: endocrine or metabolic disorders, chro-
mosomal disorders, growth failure caused by other disorders (emotional
deprivation, severe chronic illness, chondrodysplasia) or syndromes
(with the exception of the Silver Russell syndrome), and previous or
present use of drugs that could interfere with growth and GH treatment.
Mean birth length (SDS) was3.4 1.6; birth weight (SDS),2.5 1.1;
gestational age, 36.4  3.7 wk; and body mass index (BMI), (SDS)
1.3  1.2.
The control group was comprised of 170 healthy age-matched pre-
pubertal children (94 boys and 76 girls) with a normal stature born AGA
who were referred to the hospital for a minor surgical procedure. Blood
was obtained before anesthesia was given. Normal stature was defined
as a height between2 and2 SDS according to Dutch references (15).
All children were between 3 and 9 yr of age. None of the children had
a syndrome or chromosomal abnormality, endocrine or metabolic dis-
order, or any other illness or use of drugs that might have affected
DHEAS levels.
The study was approved by the Ethics Committee of each partici-
pating center. Written informed consent was obtained from the parents
or custodians of each child.
Study design
In the first part of this study, the serum DHEAS levels were compared
between the SGA group and the AGA controls. Venous blood samples
were obtained for determination of serum DHEAS levels. In the SGA
group, blood was obtained before the start of GH treatment, the inci-
dence of premature pubarche was assessed, and bone maturation was
determined.
In the second part of this study, the 1-yr effect of GH treatment (1 or
2 mg GH/m2d) on serum DHEAS levels was evaluated in the SGA
group in comparison with changes after 1 yr in a randomized untreated
SGA group. The SGA group consisted of participants of two Dutch GH
trials who met the same inclusion and exclusion criteria. All patients had
a GH stimulation test to exclude GH deficiency. The first study consisted
of 56 short SGA children who were 1:1 randomly and blindly assigned
to a group receiving either 1 mg or 2 mg GH/m2d (0.035 and 0.070
mg/kgd, respectively) (18). The second study consisted of 125 short
SGA children who were 1:2 randomly assigned to either a group without
GH treatment (untreated group) or a group receiving 1 mg GH/m2d
(0.035 mg/kgd). Together, this resulted in three study groups: an
untreated control group (n  42), a group that received 1 mg GH/m2d
(n 111), and a group treated with 2 mg GH/m2d (n 28). Biosynthetic
GH (recombinant human GH Norditropin; Novo Nordisk A/S, Bags-
vaerd, Denmark) was given sc once daily at bedtime with a pen injection
system (Nordiject 24; Novo Nordisk A/S). Every 3 months, the total GH
dose was adjusted to the calculated body surface. Venous blood samples
were obtained after 1 yr of GH treatment or nontreatment. All samples
were frozen at 80 C until assayed.
Physical examination
Before the start of GH treatment and every 3 months after the start
of GH treatment, SGA children had a physical examination including
measurement of standing height, weight, and pubertal stage. Height was
measured according to Cameron (19) using a Harpenden (Cambridge,
MD) stadiometer. Height and weight were expressed as SDS (15). Pu-
bertal stages were assessed according to Tanner (17) using an orchidom-
eter in boys. Premature pubarche was defined as the appearance of pubic
hair stage II or more before the age of 8 yr in girls and 9 yr in boys.
Hormone assays
DHEAS levels were determined in one central laboratory and mea-
sured using a chemiluminescence-based competitive immunoassay (Im-
mulite1, Diagnostic Products Corporation, Los Angeles, CA). The in-
terassay coefficient was 8%. The limit of detection was 0.2 mol/liter.
Values below this limit of detection were considered to be 0.1mol/liter.
Bone maturation
For the SGA children, an x-ray of the left hand was made before the
start of GH therapy and after 1 yr of GH treatment. All bone ages (BAs)
were determined by one investigator according to the radius, ulna, and
short bone scores of Tanner et al. (20).
Statistical analyses
Serum DHEAS levels are presented as median and interquartile
range; BAs are presented as mean sd. The SGA children and the AGA
controls were divided into various age groups: group I, 3.00–4.99 yr;
group II, 5.00–6.99 yr; and group III, 7.00–8.99 yr.
Differences in serum DHEAS levels between the SGA children and
AGA controls were tested per subgroup of age and gender. In case of
a non-Gaussian-shaped DHEAS distribution, the Mann-Whitney U test
was used. If the DHEAS distribution within a group was Gaussian-
shaped, the analysis of covariance was used with age as covariate.
Differences in BA and CA were tested using the paired-samples t test.
The Spearman rank correlation test was used to test the correlations
between serum DHEAS levels and age, BMI, and difference between CA
and BA. The correlations between DHEAS, birth weight, and birth
length were tested with the partial correlation test corrected for age at
time of study. A P value of less than 0.05 was considered significant.
TABLE 1. Age and serum DHEAS levels for boys and girls per age group in SGA children and AGA controls and BMI SDS for SGA
children
Age group
SGA children AGA controls
n Age (yr) DHEAS (mol/liter) BMI SDS n Age (yr) DHEAS (mol/liter)
Boys I 26 3.9 (3.7–4.6) 0.1 (0.1–0.3) 1.5 (1.2)a 30 3.7 (3.3–4.3) 0.1 (0.1–0.1)
II 29 6.0 (5.4–6.7) 0.1 (0.1–0.7) 1.0 (1.0)a 30 6.0 (5.4–6.4) 0.3 (0.1–0.8)
III 36 7.7 (7.2–8.3) 1.0 (0.2–2.3) 1.0 (1.1)a 34 7.9 (7.4–8.5) 0.5 (0.3–0.9)
Girls I 23 4.0 (3.5–4.5) 0.1 (0.1–0.3) 1.9 (1.6)a 26 4.3 (3.6–4.6) 0.1 (0.1–0.2)
II 37 6.2 (5.3–6.6) 0.3 (0.1–0.5) 1.5 (1.2)a 30 5.9 (5.4–6.3) 0.3 (0.2–0.4)
III 30 7.9 (7.4–8.6) 0.5 (0.2–1.2) 0.9 (1.0)a 20 7.9 (7.5–8.6) 1.2 (0.4–2.0)b
Data are expressed as median (interquartile range) except BMI SDS, which is mean (SD). Age group I, 3.00 to 4.99 yr; II, 5.00–6.99 yr; III,
7.00–8.99 yr.
a P  0.01 vs. 0 SDS.
b P  0.05, AGA vs. SGA.
Boonstra et al. • DHEAS Levels in Short Children Born SGA J Clin Endocrinol Metab, February 2004, 89(2):712–717 713
 on November 7, 2006 jcem.endojournals.orgDownloaded from 
All analyses were performed using SPSS version 10.0 (SPSS, Inc.,
Chicago, IL).
Results
Untreated SGA children vs. AGA controls
Table 1 shows the serum DHEAS levels and age in the
various age groups for the SGA children compared with the
age-matched AGA controls for boys and girls. For both the
SGA children and AGA controls, we found higher serum
DHEAS levels with increasing age. There was no significant
difference in age between the SGA group and AGA controls.
The serum DHEAS levels per age group were not higher for
the SGA group compared with AGA controls. SGA girls aged
7.00–8.99 yr had significantly lower serum DHEAS levels
compared with age-matched AGA girls (Table 1). Table 1 also
shows the BMI SDS for the SGA children. In all age groups,
the mean BMI SDS for the SGA children was significantly
lower than zero. Only one SGA boy in age group III had a
BMI SDS above 2.
For both the SGA group and AGA controls, a positive
correlation was found between serum DHEAS levels and age
(r 0.47, P 0.001; r 0.56, P 0.001, respectively). A weak
but significant negative correlation was found between se-
rum DHEAS levels and birth weight SDS and birth length
SDS in children born SGA (r  0.30, P  0.01; r  0.29,
P 0.01, respectively), but after correction for age at the time
of study the correlations disappeared. No correlation was
found between serum DHEAS levels and BMI SDS at the time
of study.
Of the 90 SGA girls, two girls had first signs of pubarche
before the age of 8 yr. Because pubic hair development at
a stage greater than stage I was not an exclusion criterion
for the GH trials, these girls were enrolled in the study at
the age of 8.5 yr. At that age serum DHEAS levels were 1.60
and 3.00 mol/liter, respectively, and BAs were 9.8 and 9.6
yr, respectively. The normal interval range for serum
DHEAS for girls aged 7.0 – 8.9 yr is 1.19 (0.37–2.00) mol/
liter. None of the boys had signs of pubarche before the age
of 9 yr.
Table 2 shows that all age groups of SGA children had a
BA delay (CA  BA), with a significantly lower mean BA
than CA (P  0.001). Until the age of 7 yr, we did not find
a correlation between serum DHEAS levels and degree of BA
delay, but after the age of 7 yr, a weak negative correlation
was found between serum DHEAS levels and degree of BA
delay (r  0.34; P  0.001).
Effect of 1 yr of GH treatment vs. no treatment
Table 3 shows that baseline clinical data were comparable
for the three study groups. The mean age of the children
receiving 2 mg GH/m2d was 11 months older than that of
the untreated group, but this age difference was not signif-
icant. Table 4 shows the age, serum DHEAS levels, and
progression of BA after 1 yr of GH treatment or no treatment.
In the oldest age group, the age was significantly different
between the three study groups. We, therefore, used the
analysis of covariance test adjusted for age. After adjusting
for age, the serum DHEAS levels of the three study groups
per age group were not significantly different between the
three SGA study groups. The progression of bone maturation
(the increase of BA divided by the increase of CA) in age
group II was significantly faster in the group receiving 2 mg
GH/m2d compared with the groups without GH treatment
and the group receiving 1 mg GH/m2d.
Discussion
We investigated the serum DHEAS levels in a large
group of 181 short prepubertal children aged 3–9 yr born
SGA in comparison with 171 age-matched AGA controls.
Our data show that short prepubertal children born SGA
have normal serum DHEAS levels, and 1 yr of GH treat-
ment had no influence on the serum DHEAS levels. Pre-
mature pubarche was found in 2.2% of the girls and in
none of the boys. Age was positively correlated with se-
rum DHEAS levels. After the age of 7 yr, a weak negative
correlation was found between serum DHEAS levels and
BA delay. No correlation was found between serum
DHEAS levels and BMI SDS.
Normal serum DHEAS levels were found in short pre-
pubertal SGA children compared with age-matched AGA
controls. SGA girls aged 7.00 – 8.99 yr had significantly
lower serum DHEAS levels compared with their AGA
controls. Previously, other studies reported higher serum
DHEAS levels in individuals born SGA (2, 7, 8, 21, 22).
However, most of these studies were much smaller and
used different definitions. For example, some studies in-
cluded individuals with low birth weight not corrected for
TABLE 2. BA compared with CA in 164 SGA children
Age group (yr) n CA (yr) BA (yr)a
I (3–4.99) 43 4.0  0.6 3.2  0.9b
II (5–6.99) 59 6.0  0.7 5.0  1.3b
III (7–8.99) 62 7.9  0.6 6.9  1.7b
Data expressed as mean  SD.
a Bone age according to the radius, ulna, and short bones scores of
Tanner et al. (20).
b P  0.001.
TABLE 3. Clinical data at start of GH trial in 181 short SGA children
SGA study groups
Untreated group 1 mg GH/m2d 2 mg GH/m2d
Male/female 19/23 57/54 15/13
Gestational age (wk) 36.3  3.5 36.6  3.7 35.6  4.1
Birth length SDS 3.7  2.3 3.3  1.2 3.6  1.7
Birth weight SDS 2.8  1.0 2.3  1.1 2.7  1.2
CA (yr) 5.8  1.5 6.1  1.6 6.7  1.9
Height SDS 3.1  0.6 3.0  0.7 3.1  0.7
Data expressed as mean  SD.
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gestational age or evaluated the effect of birth weight or
length in a group of children born AGA. In most studies,
serum DHEAS levels were studied in individuals during
or after puberty or in SGA children who underwent a
spontaneous catch-up growth after birth. Our results are
in agreement with those of a French study of normal-
statured adult women born SGA that found no differences
in serum DHEAS levels between women born SGA and an
AGA control group (9). Dahlgren et al. (23) also did not
find significantly different serum DHEAS levels in 33 short
SGA children (defined as a weight or a length at birth
below 2 SDS) compared with 35 normal-statured AGA
children. However, this study included both prepubertal
and pubertal children aged between 2.8 and 15.5 yr. To our
knowledge, our study is the first one investigating serum
DHEAS levels in a large group of prepubertal short SGA
children.
Serum DHEAS levels were positively correlated with age.
However, we did not find a correlation between birth weight
(SDS), birth length (SDS), and serum DHEAS levels in SGA
children after correction for age at the time of study. Dahl-
gren et al. (23) found a negative correlation between serum
DHEAS levels and birth weight in SGA and AGA children
together, but this correlation disappeared after the age of 9
yr. A possible explanation for this discrepancy is that these
authors did not correct for age at investigation below the age
of 9 yr, although they also found a significant correlation
between serum DHEAS levels and age.
Ibanez et al. (24) reported a significantly lower birth weight
in girls with ovarian hyperandrogenism who also had a
premature pubarche. It was concluded that girls with a pre-
mature pubarche born SGA are at higher risk of getting
polycystic ovarian syndrome (10). However, these studies
were performed in a relatively small patient group from a
specific part of Spain. Their patients presented with abnor-
malities, and the association with low birth weight was
found retrospectively. We feel that selection based on low
birth weight is more appropriate for studying the conse-
quences of a small size at birth on serum DHEAS levels at
varying prepubertal ages. In the Dutch GH trials, pubic hair
development at a stage greater than stage I was not an ex-
clusion criterion (17). Because serum DHEAS levels in our
SGA group were normal, it is not surprising that only 2.2%
of the girls and none of the boys had a premature pubarche.
This is comparable with the incidence of premature pubarche
in the normal population, in which the incidence in white
girls younger than 8 yr is 2.8% (25). One of the two SGA girls
with a premature pubarche had DHEAS levels above the
normal range.
Some studies reported a positive correlation between
weight and serum DHEAS levels. Particularly marked
weight gain and obesity were associated with high serum
DHEAS levels (26). In contrast, we did not find a correlation
between BMI SDS and serum DHEAS levels in our prepu-
bertal SGA group. One of the explanations might be that our
SGA children were lean with a mean BMI SDS significantly
lower than zero. Only one boy had a BMI SDS above 2. In
addition, there was only a narrow variation in the BMI SDS
of our prepubertal SGA children.
The SGA children had a 1-yr delay in BA that wasT
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similar for all three age groups. Mean bone maturation was
not advanced, at least not until a mean (sd) age of 7.9 (0.6)
yr, which does not exclude that acceleration of bone mat-
uration might occur at a later age as has previously been
reported. Tanner et al. (27) found an acceleration of BA
from the age of 8 yr in short children with Silver Russell
syndrome born SGA. Before the age of 7 yr, we did not find
a correlation between serum DHEAS levels and BA delay.
But, after the age of 7 yr, we found a weak but significant
negative correlation between serum DHEAS levels and BA
delay, suggesting that DHEAS might be one of the factors
responsible for the acceleration of bone maturation in SGA
children after the age of 7 yr. In addition, the two SGA girls
who had a premature pubarche showed high serum
DHEAS levels and an advanced BA.
In several studies, short SGA children are being treated
with biosynthetic GH. It is known that GH increases IGF-I
levels, and IGF-I plays an important role in the biosyn-
thesis of adrenal steroids (6, 18). For this reason, we in-
vestigated whether GH treatment might have an influence
on the adrenarche of SGA children; however, we showed
that 1 yr of GH treatment has no influence on serum
DHEAS levels in SGA children regardless of the GH dose
of 1 or 2 mg GH/m2d. The age in age group III was
significantly different between the three GH treatment
groups. For this reason, the DHEAS levels were different
after 1 yr of GH treatment, but, after correction for age,
there was no significant difference between serum DHEAS
levels in the three groups. It has also been reported that the
administration of GH in children with idiopathic GH de-
ficiency did not modify the adrenal androgen plasma lev-
els (28). These data support our data indicating that GH
treatment does not induce higher serum DHEAS levels.
After 1 yr, the progression of bone maturation was only
significantly higher in age group II patients who received
2 mg GH/m2d. However, Van Pareren et al. (29) showed
in the same group that there was no GH dose effect on bone
maturation after 5 yr of GH treatment.
In conclusion, this study shows that small size at birth,
which might be a feature of fetal growth restriction, has no
effect on serum DHEAS levels before the age of 9 yr. The
incidence of premature pubarche is comparable with the
normal population. In addition, 1 yr of GH treatment has no
effect on serum DHEAS levels.
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